Search for content, post, videos

Category

Pharma

0 COMMENT
41 Views
Asset Value

For life science companies, putting a price on their most valuable resources – ideas, research, proposals and prototypes – can be difficult. Yet the need to protect these assets is critical to preserving a company’s overall value and its ability to move any research forward. Since intellectual property often is…

acarix-ceo
0 COMMENT
38 Views
Positive results from Acarix study

Acarix has announced the results from a new multi-center trial of its handheld CADScor System for non-invasive, non-radiation acoustic detection of Coronary Artery Disease. The results were presented at the American College of Cardiology 2017 Annual Scientific Meeting held in Washington on 17-19 March 2017 and showed that the handheld…

karolinska-institutet-science-park
0 COMMENT
47 Views
Aprea enters research collaboration

Aprea Therapeutics announces a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumor suppressor protein p53 by APR-246. The goal of the collaboration is to evaluate and characterize preclinical efficacy of APR-246 in combination with multiple other anti-cancer agents and across multiple tumor types.…

lars-hedbys
0 COMMENT
34 Views
Idogen’s technology granted European patent

Idogen announces that the European Patent Office will formally grant a patent application, covering the company’s tolerogenic vaccine technology. The EPO approval strengthens the company’s patent portfolio for the vaccine technology. A patent in the same patent family has already been granted in Japan and a Notice of Allowance has…

recipharm
0 COMMENT
33 Views
Recipharm manufactures to the Japanese market

Recipharm has entered into a long term agreement with Sato Pharmaceutical for the commercial manufacture and delivery of Emla Patch to Japan. Emla Patch is used as a local anaesthetic product and will be launched under the business area of ethical pharmaceuticals at Sato. Recipharm’s facility in Karlskoga, Sweden will…

henrik-wnt
0 COMMENT
48 Views
Positive results from Wnt Research

WntResearch announces that the company has obtained positive results from the analyses of patient tumour tissue samples before and after treatment in a Phase 1b study with Foxy-5 – a drug candidate intended to inhibit tumours from spreading in cancer patients. Based on the obtained results, the company has defined…

nordic nanovector
0 COMMENT
40 Views
First patient dosed in Nordic Nanovector study

Nordic Nanovector announces that the first patient has been dosed in its Phase 1 study evaluating Betalutin (177Lu-satetraxetan-lilotomab), a novel CD37 targeting antibody-radionuclide conjugate, in patients with relapsed diffuse large B-cell lymphoma (DLBCL) – the “LYMRIT 37-05” trial. “We are excited to begin this study to evaluate Betalutin in patients…

oncology-antibody-astrazeneca
0 COMMENT
24 Views
New data from AZ’s Phase III solo-2 study

AstraZeneca presented results from the Phase III SOLO-2 trial demonstrating a significant improvement in progression-free survival in germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer patients treated with Lynparza tablets compared with placebo in the maintenance setting. PFS as measured by Blinded Independent Central Review (BICR)evaluation, a pre-specified analysis supporting the primary…

immunovia
0 COMMENT
3 Views
Immunovia’s retrospective autoimmune disease study has been finalized

Immunovia announces that the large retrospective autoimmune disease study, performed in collaboration with Lund University’s IDEA Centre has been finalized. The study, first reported in January 2017, included 315 blood samples and was specifically designed to assess the effectiveness of IMMray blood-based biomarker signatures in differentiating SLE from three other…

leo-pharma-research
0 COMMENT
2 Views
LEO Pharma announces positive clinical trial results

LEO Pharma announces positive results from a Phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD), a serious and chronic form of eczema. Tralokinumab is an investigational monoclonal antibody that specifically targets the cytokine IL-13,which plays an important role in…

sobi-study
0 COMMENT
2 Views
Sobi receives approval from the EMA

Swedish Orphan Biovitrum has received approval from the European Medicines Agency (EMA) for the grouped type II 15 K Variation for Elocta (efmoroctocog alfa). The variation involves several changes, including the approval of Elocta drug substance manufacturing in 15 000 litre scale bioreactors.  Elocta is a recombinant extended half-life factor VIII…